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As in previous years, Intensive Care
Medicine published numerous articles
dedicated to infection and sepsis, mostly
focussing on pneumonia and related
problems.
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Community-acquired pneumonia
Different pathogens, variable virulence in different strains
of microorganisms, increasing age, and underlying dis-
eases undoubtedly have an important impact on
community-acquired pneumonia (CAP) morbidity and
mortality, but genetic variability affecting the host
response may also influence susceptibility and outcome
[1]. This is why Martin-Loeches and colleagues [2]
assessed the genetic variability at IL6 in a large cohort of
1,227 white Spanish patients with CAP, of whom 306 had
pneumococcal CAP (P-CAP). In patients with P-CAP
multivariate analysis adjusted for age, gender, co-mor-
bidity, hospital of origin, and severity showed that the IL6
-174 GG genotype was protective against the develop-
ment of ARDS, septic shock, and multiple organ
dysfunction syndrome. This effect was higher than that
observed in patients with CAP, irrespective of the causal
pathogen involved.
Ventilator-associated pneumonia
Whether azithromycin, a drug that could block the quo-
rum-sensing (QS) system, could prevent ventilator-
associated pneumonia (VAP) in patients colonized by
rhamnolipid-producing isolates is unknown. To test this
hypothesis, Van Delden and colleagues [3] randomized 92
patients proven to be colonized by Pseudomonas aeru-
ginosa, to receive either placebo or 300 mg/day iv
azithromycin in a double-blind fashion for a maximum of
20 days. Considering only the subgroup of patients at
very high risk of developing VAP because they were
colonized by isolates producing intermediate or high
levels of rhamnolipids (n = 41), the incidence of VAP
was reduced fivefold in azithromycin versus placebo
patients (1/5 vs. 5/5 VAP, p = 0.048). These data stress
the need for a large phase IIb clinical trial restricted to
patients colonized by QS-proficient isolates to further
establish safety and efficacy of QS inhibition by azith-
romycin to prevent P. aeruginosa VAP.
Fungal airway colonization is a frequent finding in
patients submitted to mechanical ventilation (MV) and
could promote VAP development, especially if caused by
P. aeruginosa, a bacterium likely to become resistant to
antimicrobial agents. Indeed, a growing body of evidence
supports the strong interplay between Candida albicans
and P. aeruginosa when coexisting within a biofilm
environment such as the endotracheal tube or the airway
[4, 5]. In a prospective study of 323 consecutive cases of
suspected VAP, Hamet et al. [6] were able to demonstrate
that mortality rate was greater in patients with fungal
airway colonization than in those without (44 vs. 31 %,
p = 0.02). Moreover, Candida spp. airway colonization
was an independent risk factor for multidrug-resistant
bacteria isolation, such as P. aeruginosa and Enterobac-
teriaceae [odds ratio (OR) 1.79, 95 % confidence interval
(CI) 1.05–3.05; p = 0.03], in addition to the time elapsed
between ICU admission and VAP suspicion. Whether or
not Candida spp. airway colonization should be consid-
ered when selecting an empiric antibiotic treatment for
VAP will require additional studies, as well as for
defining the clinical utility of antifungal drugs in such
patients [7].
Etomidate has a favorable hemodynamic profile and is
frequently used as a single bolus for rapid sequence
intubation in trauma patients, as well as ICU patients.
However, its use can induce transient corticosteroid
insufficiency and thus increases susceptibility to noso-
comial infection [8]. To investigate the impact of
etomidate on the rate of hospital-acquired pneumonia
(HAP) in trauma patients and the effects of hydrocorti-
sone in etomidate-treated patients, Asehnoune and
colleagues [9, 10] did a post hoc analysis of the HYP-
OLYTE double-blind, placebo-controlled trial of
hydrocortisone in trauma patients. The administration of
etomidate did not alter basal cortisolemia, but it did
decrease the delta of cortisolemia at 60 min, leading to
corticosteroid insufficiency in 83 % of the patients
(p = 0.007). Forty-nine (52 %) patients with etomidate
and 16 (30 %) patients without etomidate developed
pneumonia by day 28, respectively (p = 0.009). Among
etomidate-exposed patients, hydrocortisone was found to
significantly decrease the rate of HAP and the duration of
MV. These data should alert physicians to limit the use of
etomidate for the intubation of severe trauma patients
unless they use hydrocortisone to counteract the delete-
rious effects of the drug.
Treatment of VAP is increasingly hampered by anti-
biotic resistance and an innovative approach is to
augment antibiotic delivery at the site of infection.
Nebulized colistimethate sodium (CMS)/colistin is
frequently used as an adjunctive therapy for the treat-
ment of VAP in patients infected by very difficult-to-
treat pathogens, such as carbapenemase-producing
Klebsiella pneumoniae or multiresistant strains of
P. aeruginosa or Acinetobacter baumannii. However,
very little information is available regarding the phar-
macokinetics of the drug when used by aerosolization
in ventilated patients. To fill this gap, Athanassa and
colleagues [11] determined colistin concentrations in
bronchoalveolar lavage fluid and serum of 20 patients
mechanically ventilated, who had symptoms and signs
suggestive of ventilator-associated tracheobronchitis
caused by gram-negative bacilli only susceptible to
polymyxin and who were treated by colistin inhalation
at a dose of 1 MU (80 mg CMS) every 8 h via a
vibrating-mesh nebulizer. Results demonstrated rela-
tively high colistin concentrations in the epithelial
lining fluid at 1 and 4 h and substantially lower con-
centrations at 8 h after inhalation, underlining that a
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dose of 80 mg of inhaled CMS every 8 h may not be
adequate for the treatment of patients with VAP due to
multidrug-resistant gram-negative bacteria (GNB).
Additional studies are required to determine whether
larger doses of nebulized CMS may result in higher and
sustained colistin concentrations at the target site in
pulmonary infections.
A newly designed device for nebulizing amikacin
(BAY41-6551) was used to treat 69 patients with VAP in
a randomized, placebo-controlled, double-blind phase II
study. Treatment was well tolerated and associated with
good clinical cure rates that warrant further clinical
evaluation [12].
Gram-negative bacteria predominate in HAP, and
among them, Escherichia coli is the main Enterobacteri-
aceae involved in VAP. Phylogenetic analysis shows that
E. coli population can be divided into four major groups
(A, B1, B2, and D). Strains belonging to groups A and B1
are known to carry few genes encoding virulence factors
(VF), with weak extraintestinal pathogenicity, and are
commonly multidrug-resistant. On the other hand, group
B2 and D strains typically express numerous VF medi-
ating bacterial adhesion, cell host invasion, and toxicity,
and usually exert high extraintestinal pathogenicity [13].
To provide a detailed analysis of E. coli strains colonizing
and infecting ICU patients, Messika and colleagues [14]
screened 132 consecutive ICU patients ventilated for
longer than 3 days for simultaneous presence of E. coli in
rectal, oropharyngeal, and respiratory samples (coloniza-
tion or VAP). If present, E. coli isolates were
characterized by antimicrobial susceptibility, phyloge-
netic grouping, and VF gene content. The authors found
that multisite colonization with E. coli was frequent,
observed in 19 % of the patients. The majority of isolates
belonged to phylogenetic group B2, characterized by high
VF gene content and low antimicrobial resistance. Among
screened VF genes, iron uptake genes such as iroN and
sfa appeared important for lung infection. Targeting the
associated proteins by way of vaccines or monoclonal
antibodies may help establish novel therapeutic strategies
in that setting.
H1N1
Pulmonary complications in the course of systemic
infection might be clinically relevant. Although some
isolated case reports of H1N1-associated rhabdomyolysis
have been published, uncertainty still remains regarding
the clinical implications of elevated creatine kinase (CK)
levels in this setting [15]. To assess if increased CK was
related to worse global, renal, and respiratory outcomes in
critically ill patients with H1N1 infection, and if it could
serve as a biomarker of severity, Borgatta and colleagues
[16] retrospectively analyzed data gathered from 505
patients with confirmed H1N1 severe infection in Spain.
They found that slight elevations were associated with
increased pulmonary and kidney complications as well as
increased length of stay (both ICU and hospital). Fur-
thermore, starting from CK greater than 500 UI/l, a
breakpoint close to normal upper values, significant
associations with worse renal outcomes were docu-
mented. These included higher occurrence of acute
kidney injury (AKI), as well as more frequent need for
renal replacement therapy, which progressively increased
with rising CK values. Greater pulmonary injury was
observed from CK greater than 1,000 UI/l, with 50 %
more involvement in chest radiograph in addition to more
prolonged MV.
Early use of corticosteroids in patients affected by
pandemic H1N1 influenza A infection, although relatively
common, remains highly debated and might lead to
opportunistic infections by Aspergillus fungi. Of 40 crit-
ically ill patients with confirmed H1N1 infection, 9
(23 %) developed invasive pulmonary aspergillosis (IPA)
3 days after ICU admission [17]. On multivariate analy-
sis, use of corticosteroids before ICU admission was
independently associated with IPA (OR 14.4, p = 0.007),
confirming that early use of corticosteroids in patients
affected by pandemic H1N1 influenza A infection did not
result in better outcomes and was associated with an
increased risk of superinfection.
Since there are no guidelines for the design and con-
duct of randomized trials in pandemic critical illness,
Annane et al. [18] presented their recommendations based
on the experience they acquired during a multicenter
randomized trial performed in ICU patients with 2009
H1N1 influenza pandemia. The authors report how they
carried out a multicenter, randomized, placebo-controlled,
double-blind trial of corticosteroids in ICU patients with
2009 H1N1 influenza pneumonia requiring MV. The
feasibility of and hurdles in designing and initiating a
phase III trial in a short-lived pandemic crisis were ana-
lyzed. The peak of the wave was missed by 2–3 weeks
and only 26 patients were randomized. The two main
reasons for non-inclusion were patients’ admission before
the beginning of the trial and ICU personnel overwhelmed
by clinical duties. Parallel rather than sequential regula-
tory and ethics approval, and preparation and masking of
study drugs by local pharmacists would have allowed the
study to start 1 month earlier. A dedicated research team
in each participating center would have increased the ratio
of screened to randomized patients. It was concluded that
future pandemic research should consider an adaptive
design.
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Other infections and sepsis
The spread of extended-spectrum beta-lactamase (ESBL)-
producing Enterobacteriaceae, notably E. coli and K.
pneumoniae, to the community, and the need for prudent
use of carbapenems require updated studies to identify
current risk factors for colonization with ESBL-producing
isolates in patients admitted to the ICU. To do that,
Razazi and colleagues [19] conducted an 8-month pro-
spective study in the medical ICU of an 850-bed general
and university-affiliated hospital in France. ESBL-pro-
ducing Enterobacteriaceae caused 3 % of the infections
diagnosed on admission. By multivariable analysis,
transfer from another ICU, hospital admission in another
country, surgery within the past year, prior neurologic
disease, and prior administration of third-generation
cephalosporin (within 3–12 months before ICU admis-
sion) were independent predictive factors of
colonization by ESBL-producing isolates upon ICU
admission. In carriers, ESBL-strains caused 10 and 27 %
of first and second episodes of ICU-acquired infections,
respectively. These data may be useful for identifying
which ICU patients really warrant empiric therapy with
carbapenems for targeting ESBL-producing Enterobacte-
riaceae, and thus they may contribute to more efficient
antibiotic stewardship programs to help control these
organisms.
The recent increase in drug-resistant microorganisms
complicates the management of hospital-acquired blood-
stream infections (HA-BSIs). To investigate the
epidemiology of HA-BSI and evaluate the impact of drug
resistance on outcomes of ICU patients, controlling for
patient characteristics and infection management, Tabah
and colleagues [20] conducted a large, prospective, mul-
ticenter cohort study in 162 ICUs in 24 countries,
enrolling a total of 1,156 patients who had developed such
an infection. Overall, 48 % of isolates were multidrug-
resistant, including 20.5 % extensively resistant, and
0.4 % pan-drug-resistant. The 28-day all-cause fatality
rate was 36 %. Inadequate antibiotic treatment and failure
to control the source of infection were both associated
with 28-day mortality, independently from age, chronic
co-morbidities, severity of acute illness, shock, and organ
dysfunctions. Antimicrobial resistance was associated
with a significantly longer time to adequate antimicrobial
treatment and with a higher risk of death, even after
controlling for adequacy of antimicrobial treatment.
Intensified efforts to prevent HA-BSIs and to optimize
their management through adequate source control and
antibiotic therapy are clearly needed to improve
outcomes.
Catheter-related infections (CRI) are an important
source of HA-BSIs and represent relevant complications
in ICU patients, although considerable achievements in
infection prevention have been realized. In 51 French
ICUs the overall CRI rate was 2.2 per 1,000 central
venous catheter days in 7,188 patients and identified risk
factors for CRI amenable for improvement were the
preference of the subclavian route and the use of an
antiseptic solution containing alcohol [21]. In a random-
ized study of 78 ICU patients with acute renal failure
requiring hemodialysis, sodium citrate catheter locks
were, as compared to saline locks, associated with less
catheter complications, longer catheter life span, but
comparable incidence of infections [22]. Another impor-
tant infectious complication of treatment in ICU is the
invasive candidiasis (IC). In a prospective study of 176
non-neutropenic patients with severe abdominal condi-
tions at ICU admission and expected to stay at least
7 days, the value of (1?3)-b-D-glucan (BDG), C. albi-
cans germ tube antibody (CAGTA), C-reactive protein
(CRP), and procalcitonin (PCT) levels were assessed for
the diagnosis of IC and for differentiating Candida spp.
colonization from infection. BDG with a positive test for
CAGTA accurately differentiated Candida colonization
from IC with an area under the curve of 0.78 (95 % CI
0.76–0.81). CRP and PCT were less discriminatory [23].
Duration of the antibiotic treatment still remains a
controversial problem. The European Society of Intensive
Care Medicine (ESICM) working group performed a
systematic review and meta-analysis of randomized
clinical trials (RCTs) to determine whether plasma PCT
determination can be used as a guide in order to shorten
and optimize the duration of antibiotic therapy strategies
for critically ill adult patients [24]. Seven evaluable RCTs
were identified and analyzed. Primary outcomes included
the duration of antibiotic therapy for the first episode of
infection and 28-day mortality. Secondary outcomes
included length of ICU stay, length of hospitalization,
antibiotic-free days within the first 28 days of hospital-
ization, recurrences, and superinfections. The authors
found that the duration of antibiotic therapy for the first
episode of infection was reduced in favor of PCT-guided
treatment [pooled weighted mean difference
(WMD) = -3.15 days, random effects model, 95 % CI
-4.36 to -1.95, p \ 0.001]. There was no difference in
28-day mortality between the compared arms [fixed effect
model (FEM), OR 0.96, 95 % CI 0.79–1.15, p = 0.63).
Antibiotic-free days were increased within the first
28 days of hospitalization in favor of the PCT-guided
treatment arm (pooled WMD = 3.08 days, FEM, 95 %
CI 2.06–4.10, p \ 0.001). No difference was found
regarding the remaining outcomes. It was concluded that
PCT-guided antibiotic therapy algorithms could help in
reducing the duration of antimicrobial administration
without having a negative impact on survival.
The increased number of infections caused by anti-
microbial-resistant bacteria (AMRB) is increasing
worldwide. Chlorhexidine body washing (CHG-BW) has
been proposed as a measure to limit the spread of AMRB.
Cross-transmission of AMRB is extremely important and
temporarily contaminated hands of health-care workers
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are considered the most important vectors for spread.
Derde et al. [25] systematically assessed the evidence on
the effectiveness of CHG-BW in reducing colonization
and infection with AMRB in adult ICU patients. Data
from 16 studies were extracted; 9 were excluded because
of assessed high risk of bias or inadequate analyses. The
remaining studies differed markedly in interventions/co-
interventions and case mix which precluded pooling of
data in a formal meta-analysis, but overall the quality of
the studies was good. It was found that the incidences
of methicillin-resistant Staphylococcus aureus (MRSA)
acquisition were reduced significantly in three studies in
which this was the primary endpoint. A significant
reduction in MRSA infection rates was observed in only
one of five studies. The carriage and bacteremia rates of
vancomycin-resistant enterococcus (VRE) were assessed
in one study, and both significantly declined. Finally,
there were hardly any data on the effects of CHG-BW on
antibiotic-resistant gram-negative bacteria (ARGNB). It
was concluded that CHG-BW may be effective in pre-
venting carriage, and possibly BSIs, with MRSA and
VRE in different ICU settings. As CHG-BW protocols,
co-interventions, and case mix varied widely, the attri-
bution of these effects to CHG-BW alone should be done
with care. Evidence that CHG-BW reduces carriage of or
infections with ARGNB is lacking.
Gut overgrowth happens in the critically ill requiring
intensive care. Gut overgrowth is the crucial event which
precedes both primary and secondary endogenous infec-
tion and is a risk factor for the development of de novo
resistance. Selective decontamination of the digestive
tract (SDD) is an antimicrobial prophylaxis designed to
control overgrowth. In a review article Silvestri et al. [26]
revised the mechanisms of action of SDD. Data assessed
by the authors show that the full SDD regimen using
parenteral and enteral antimicrobials reduces lower air-
way infection by 72 %, bloodstream infection by 37 %,
and mortality by 29 %. Resistance is also controlled.
Parenteral cefotaxime which reaches high salivary and
biliary concentrations eradicates overgrowth of ‘normal’
bacteria such as S. aureus in the throat. Enteral polyenes
control ‘normal’ Candida species. Enteral polymyxin and
tobramycin eradicate or prevent gut overgrowth of
‘abnormal’ ARGNB. Enteral vancomycin controls over-
growth of ‘abnormal’ MSRA. SDD controls overgrowth
by achieving high antimicrobial concentrations effective
against ‘normal’ and ‘abnormal’ potential pathogens
rather than by selectivity.
Early identification of infection and sepsis is crucial.
Systemic levels of soluble urokinase-type plasminogen
activator receptor (suPAR) positively correlate with the
activation level of the immune system. Backes et al. [27]
reviewed the usefulness of systemic levels of suPAR in
the care of critically ill patients with sepsis, SIRS, and
bacteremia, focusing on its diagnostic and prognostic
value. Ten papers on original studies of critically ill
patients were identified that report on suPAR in sepsis,
SIRS, or bacteremia. Systematic levels of suPAR have
little diagnostic value in critically ill patients with sepsis,
SIRS, or bacteremia. Systemic levels of suPAR, how-
ever, have superior prognostic power over other
commonly used biological markers in these patients.
Mortality prediction by other biological markers or
severity-of-disease classification system scores improves
when combining them with suPAR. Systemic levels of
suPAR correlate positively with markers of organ dys-
function and severity-of-disease classification system
scores. Notably, the type of assay used to measure su-
PAR, the age of the patients, and underlying disease
affect systemic levels of suPAR. The authors concluded
that the diagnostic value of suPAR is low in patients
with sepsis and infections and that the studies are limited
to the predictive potential to estimate the mortality risk
in observational designs.
The largest part of the sepsis burden occurs in mid-
dle- and low-income countries, and guidelines developed
in high-income countries cannot be implemented in most
middle- and low-income countries because lack of
resources. Dunser et al. [28], representing a working
group of the ESICM, provide a set of affordable rec-
ommendations for clinicians practicing in resource-
limited settings in order to improve the management of
pediatric and adult septic patients. Recommendations are
grouped into acute and post-acute interventions. Acute
interventions include liberal fluid resuscitation to
achieve adequate tissue perfusion, use of epinephrine or
dopamine for inadequate tissue perfusion despite fluid
resuscitation, measurement of arterial blood pressure in
hemodynamically unstable patients, administration of
hydrocortisone or prednisolone to patients requiring
catecholamines, oxygen administration to achieve an
oxygen saturation greater than 90 %, semi-recumbent
and/or lateral position, non-invasive ventilation for
increased work of breathing or hypoxemia despite oxy-
gen therapy, administration of adequate antimicrobials,
investigation for infectious source identification, fluid/
tissue sampling and microbiological work-up, removal,
drainage, or debridement of the infectious source. Post-
acute interventions include regular re-assessment of
antimicrobial therapy, administration of antimicrobials
for an adequate but not prolonged duration, avoidance of
hypoglycemia, pharmacological or mechanical deep vein
thrombosis prophylaxis, resumption of oral food intake
after resuscitation and regaining of consciousness, care-
ful use of opioids and sedatives, early mobilization, and
active weaning of invasive support. The authors con-
cluded that scarce evidence exists for the management of
pediatric and adult sepsis in resource-limited settings.
These recommendations were endorsed by ESICM, the
World Federation of Pediatric Intensive and Critical
Care Societies (WFPICCS), the Global Sepsis Alliance
(GSA), the Federation of Austrian Societies of Intensive
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Care Medicine (FASICM), the Ugandan Society of
Intensive Care Medicine (USICM), and the Mongolian
Society of Anesthesiology and Intensive Care Medicine
(MSAICM).
Sepsis is a complex syndrome and adjunctive therapies
to the conventional treatment might be of some benefit.
Acetyl salicylic acid (ASA, aspirin) and non-steroidal
anti-inflammatory drugs (NSAIDs) may have potential as
adjunctive agents for sepsis. A review article [29] dis-
cussed the basis for sepsis therapy with ASA. ASA and
NSAIDs have beneficial effects in numerous experimental
models of sepsis. Low doses of ASA of 100 mg/day or
less trigger synthesis of lipoxins, which are anti-inflam-
matory and aid in resolution of inflammation. Higher
doses of ASA and NSAIDs act to reduce NF-jB stimu-
lation and inhibit numerous septic pathways. While a
previous randomized controlled trial of ibuprofen failed to
show a reduction in mortality in sepsis, it did reduce
clinical manifestations of sepsis. More recent observa-
tional studies have shown reduction in sepsis or acute
lung injury leading to lower mortality in ICU patients
treated with ASA. The author concluded that low-dose
ASA appears to be beneficial in the prevention and
treatment of sepsis and SIRS. If proven, this intervention
would have a major, cost-effective impact on sepsis care.
Rare infections can be caused by criminal actions. A
fraudulent use of Bacillus anthracis (anthrax) can be
highly lethal. Two recent outbreaks related to contami-
nated mail in the USA and heroin in the UK and Europe
and its potential as a bioterrorist weapon have greatly
increased concerns over anthrax in the developed world.
Hicks et al. [30] summarized the microbiology, patho-
genesis, diagnosis, and management of anthrax.
B. anthracis, a gram-positive bacterium, has typically
been associated with three forms of infection: cutaneous,
gastrointestinal, and inhalational. However, the anthrax
outbreak among injection drug users has emphasized the
importance of what is now considered a fourth disease
form (i.e., injectional anthrax) that is characterized by
severe soft tissue infection. While cutaneous anthrax is
most common, its early stages are distinct and prompt
appropriate treatment commonly produces a good out-
come. However, early symptoms with the other three
disease forms can be non-specific and mistaken for less
lethal conditions. As a result, patients with gastrointesti-
nal, inhalational, or injectional anthrax may have
advanced infection at presentation that can be highly
lethal. Once anthrax is suspected, the diagnosis can usu-
ally be made with gram stain and culture from blood or
tissue followed by confirmatory testing (e.g., PCR). While
antibiotics (ciprofloxacin/doxycycline/clindamycin) are
the mainstay of anthrax treatment, use of adjunctive
therapies such as anthrax toxin antagonists are a consid-
eration. Prompt surgical therapy appears to be important
for successful management of injectional anthrax.
Coagulation and hemostasis
Coagulation balances are considerably modified in severe
ICU patients. Sepsis induces hypercoagulability, hypofi-
brinolysis, microthrombosis, and endothelial dysfunction
leading to multiple organ failure. Recently, thrombin
generation tests (TG) and point-of-care thromboelastog-
raphy (TEG) or thromboelastometry emerged as dynamic
global tests of hemostasis. Massion et al. [31] prospec-
tively investigated analytical coagulation tests, TG assays,
and thromboelastometric analyses from admission to day
7 in 29 patients with septic shock. The levels of most
procoagulant factors were increased, as well as both
delayed time and deficit in TG. Interestingly, prolonged
aPTT (p = 0.007) and persistence of TG deficit
(p = 0.024) on day 3 were independent predictors of
mortality, independently from APACHE II score. The
mechanisms of persistent coagulopathy as a potential new
therapeutic avenue need further investigations.
Bleeding and thrombotic events are common in ICU.
Bleeding events are common complications in patients
with extracorporeal life support (ECLS) usually owing to
mixed factors. Also, ECLS may promote high molecular
weight multimers of Von Willebrand factor to uncoil and
to be cleaved into less effective smaller multimers. It
leads to acquired Von Willebrand syndrome (AVWS). In
a prospective observational study, Heilmann and col-
leagues [32] confirmed that AVWS during ECLS was
almost constant (31/32 patients) and associated with
bleeding events in 22 cases. The relative contribution of
AVWS and other coagulation disorders in bleeding events
remained to be studied.
Even when standard of care subcutaneous prophylaxis
is administrated, proximal deep venous thrombosis (DVT)
rates in ICU patients may reach rates as high as 44 %. The
thromboprophylaxis use in ICU does not follow interna-
tional guidelines. In a survey performed in 59 Austrian
ICUs, despite a median of four risk factors of DVT, the
implementation of pharmacological and mechanical
methods for thromboprophylaxis is only applied in 39 %
of patients, whereas 5 % of the patients did not receive
thromboprophylaxis at all. Current practice of thrombo-
prophylaxis is predominantly based on the administration
of low molecular weight heparins prescribed at rather
arbitrary doses without a discernible relationship to drug
monitoring, thromboembolic risk factors, vasopressor use,
or fluid balance. The poor application of guidelines may
reflect limited level of proof of the recommendation, or
insufficient communication and physician knowledge of
the guidelines [33].
Cheng et al. [34] confirmed that usual thrombopro-
phylaxis is likely not adequate for ICU patients. Fifty
patients from a surgical ICU having had major abdominal
surgery for cancer were randomly allocated to either
unfractionated heparin, subcutaneously three times daily
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(SQH) versus unfractionated heparin via intravenous
infusion, titrated to an activated partial thromboplastin
time of 40–45 s (IVH). Patients in the SQH group had no
detectable peak anti-factor Xa (aFXa) activity for 5 days
after surgery, whereas patients in the IVH group had
statistically elevated levels compared to the SQH group
on days 3–5. SQH patients demonstrated a hypercoagu-
lable profile, whereas IVH patients displayed a normal
profile. Current dosing schedules of unfractionated hep-
arin for VTE prophylaxis may therefore be inappropriate
in post-surgical ICU patients with cancer.
Hemodynamic and cardiovascular
Tissue oxygen saturation: prognostic values and effect
of pressure and vasoconstriction
Guidelines on the hemodynamic management of patients
with septic shock focus on macro hemodynamic param-
eters. Early manipulation of these variables, when
coupled with treatment aiming at optimizing perfusion,
namely monitoring central venous saturation (ScVO2) or
lactate clearance [35–37], has been associated with an
improvement in outcome. Recently microcirculation was
shown to provide additional information in the context of
sepsis [38]; its assessment can provide extra information
about prognostication in this population. Assessment of
the microcirculation can be done with different devices.
Near infrared spectroscopy (NIRS) technology has been
used to assess tissue saturation in different clinical set-
tings [38, 39]. It is the dynamic assessment of changes in
theStO2 during a veno-occlusive test (VOT) that have
demonstrated the most promising results in terms of
prognostication in septic patients [40, 41]. VOT slopes,
evaluated as StO2 deoxygenation (DeOx) and the StO2
reoxygenation rate (ReOx), can be affected by the mean
arterial pressure (MAP), even when these changes occur
during vasopressor therapy [42]. Whether the prognostic
values of DeOx and ReOx are affected when the MAP has
been restored after the resuscitation phase was not known.
Mesquida et al. [43] tried to answer this question in a
study in 33 patients with septic shock in which a MAP
greater than 65 mmHg had been restored with fluids and
vasopressors. They looked at VOT slopes, MAP,
sequential organ failure assessment (SOFA) scores,
mortality, length of ICU, and length of hospital stay. They
did find a strong correlation between the VOT slopes and
MAP. Patients in which the SOFA score improved had
more negative DeOx slopes. DeOx slope values were
associated with no SOFA improvement with an OR of
1.48 (CI 95 % 1.00–2.2, p = 0.05). Impairment in both
DeOx and ReOx was associated with longer ICU and
hospital stay. When correcting for MAP, DeOx was still
associated with a worse outcome. In practice, while VOT
slopes have prognostic implications, their values have to
be interpreted in view of MAP value, too.
Peripheral vasoconstriction influences thenar oxygen
saturation as measured by NIRS
Thenar StO2 and VOT slopes were studied by Lima et al.
[44] to investigate the effect of peripheral vasoconstric-
tion on the readings of thenar StO2 measured by NIRS. In
an elegant study on healthy volunteers they explored
whether peripheral vasoconstriction can affect the read-
ings made by Inspectra model 650 (Hutchinson
Technologies, Hutchinson, KS, USA), a device based on
NIRS technology. Subjects were continuously monitored
while actively cooled with a circulating cold-water blan-
ket. The cooling process was controlled in order to avoid
changes in the core temperature. Absolute values of StO2
and VOT slopes were recorded at different time intervals
during the cooling and rewarming process. At the same
time other measurements of macro-hemodynamics such
as MAP, cardiac output (CO), and stroke volume (SV)
were taken. During the controlled cooling process, MAP,
CO, and SV did not change significantly, whereas StO2
significantly decreased. There were also significant
changes in the VOT re-oxygenation slope values associ-
ated with cooling. In practice, even without significant
changes in systemic hemodynamic variables, peripheral
vasoconstriction induced significant changes in the
peripheral perfusion. This may have important implica-
tions when assessing thenar StO2 in critically ill patients.
In fact, during the acute phase of shock, vasoconstriction
is often present and it is therefore possible that observed
changes in StO2 happen as a result of this [45, 46]. The
fact that SV, CO, and MAP did not change significantly
during the cooling process is in line with other studies
where changes in macro-hemodynamics did not correlate
with changes in peripheral perfusion and measurements of
StO2 [47]. Vascular tone can change often occur in crit-
ically ill patients and the results of this study suggest that
peripheral vasoconstriction can markedly influence the
readings of NIRS.
Knee area tissue oxygen saturation is predictive of
14-day mortality in septic shock. A group of investigators
explored the prognostic value of NIRS in different areas
of the body. Ait-Oufella et al. [48] studied whether StO2
measured around the knees can have a prognostic value in
septic shock. The hypothesis was that, because mottling
of the skin in patients with septic shock often tends to be
more pronounced around the knees, then this area could
be investigated in terms of prognostication of mortality
and compared to a validated measurement such the thenar
StO2. The authors compared knee StO2 and thenar StO2 at
different time intervals during the stabilization phase of
patients admitted with septic shock. They then looked at
the association of 14-day mortality with knee StO2 and
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thenar StO2 during this evaluation. At 6 h after hemo-
dynamic stabilization knee StO2 was significantly lower
in 14-day non-survivors compared to survivors. Thenar
StO2 was also lower at 12, 18, and 24 h but less predictive
than knee StO2. When looking at other variables associ-
ated with outcome at 14 days, 6 h arterial lactate, urinary
output, and ScVO2 were also associated with mortality.
After correcting for these factors, knee StO2 remained
associated with mortality, showing it to be an independent
predictor of mortality at 14 days in patients with septic
shock.
Neutrophils: what is their role in the microcirculation?
Neutrophils are known to play a key role in sepsis. They
represent a natural defense against bacterial infections,
indeed neutropenia has been associated with increased
susceptibility to infection. Despite this, activated leuko-
cytes are also involved in pathophysiological processes
that lead to organ injury [49]. For instance their patho-
logical role has been demonstrated in mechanisms leading
to endothelial dysfunction and during ischemia reperfu-
sion injuries [50]. Confirmation to this theory comes also
from experimental models where leukodepletion has been
associated with a protective effect against reperfusion
injuries [51]. The effect of neutropenia on the microcir-
culation in sepsis on humans was investigated in a study
by Karvunidis et al. [52]. They studied the microcircu-
lation via an orthogonal polarization spectral (OPS)
imaging device in patients with septic shock, with and
without neutropenia (defined as neutrophil count less than
1 9 109/l), and in patients in which neutropenia was
drug-induced. They also used a group of healthy volun-
teers as a control group. They did not find any difference
in septic patients with or without neutropenia. Interest-
ingly even in the chemotherapy-induced neutropenia
group, there were similar alterations in the microcircula-
tion. While neutrophil depletion has been hypothesized
as a possible protective measure against sepsis-induced
changes in the microcirculation, this study did not
show any significant protective effect of neutropenia
on the microcirculation, when assessing it with OPS
examination.
Guytonian physiology at the bedside
The mean systemic filling pressure (Pmsf) is the pressure
anywhere in the circulation during circulatory arrest.
According to the theory by Guyton [53] the venous return
is a function of the gradient between the Pmsf and the right
atrial pressure. Venous return equals CO, so estimating
Pmsf at the bedside could represent an important func-
tional measure of effective intravascular volume status.
Maas et al. [54] compared three methods to estimate the
Pmsf at the bedside. They used a previously validated
method, namely the extrapolation for zero CO of central
venous pressure (CVP)–CO pairs, during inspiratory hold
maneuvers [55]; they also used a rapid arterial occlusion
test (Parm) and an estimation of the Pmsa from a new
device called a Navigator (Applied Physiology, Sydney,
Australia). Parm assumes that during a rapid occlusion at a
specific time point (after 25–30 s of stop flow) the arterial
pressure equalizes the venous pressure, therefore allowing
this test to estimate Pmsf. Pmsa derives from a complex
software algorithm that integrates CO, CVP, and MAP.
Parm and Pmsf showed very good agreement with minimal
bias and narrow limits of agreement. During changes in
the Pmsf induced by either volume expansion or by a head
tilt up both new methods, Parm and Pmsa, tracked changes
in the Pmsf accurately.
Improving left ventricular relaxation with volume
expansion in patients with septic shock
Diastolic dysfunction is not uncommon in patients with
sepsis and septic shock [56]. Finding ways to improve
ventricular relaxation represents an important part of
therapy in these patients. To explore whether volume
expansion, by improving SV and therefore myocardial
perfusion, could have a role in improving relaxation,
Mahjoub et al. [57] performed an echocardiographic
study during rapid volume expansion in septic shock
patients. They looked at the peak velocity of the mitral
annulus early wave during diastole (E0) and the E/E0 ratio
(an index correlated to filling pressures such as the pul-
monary artery occlusion pressure, PAOP) during rapid
volume expansion. They found that in patients responding
to fluids (defined as patients in which volume expansion
produced an SV increase by more than 15 %) E0 increased
markedly only in responders with diastolic dysfunction,
whereas it did not increase significantly in responders
without diastolic dysfunction. This demonstrates that in
patients with diastolic dysfunction responding to fluids,
there is a concomitant improvement in relaxation. Inter-
estingly, in non-responders there was a significant
increase in the E/E0 ratio, i.e., identifying an increase in
filling pressure during volume loading. This index could
possibly identify patients in which fluid expansion is not
tolerated.
Completely non-invasive continuous blood pressure
measurement in ICU
The ability to continuously monitor a physiological var-
iable at the bedside is one of the cornerstones of intensive
care medicine. A new technology, the T-line 200 (Tensys
Medical, San Diego, CA, USA) based on arterial to-
nometry has recently become available. Saugel et al. [58]
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investigated the agreement of the T-line 200 with invasive
arterial blood pressure in 28 intensive care patients. They
found good bias (?0.47 mmHg) comparing non-invasive
MAP to invasive MAP, with limits of agreement between
-16.53 and ?17.46 mmHg. For systolic arterial pressure
(SAP), bias and limits of agreement were -9.01 (-37.47
to 19.45) mmHg and for diastolic arterial pressure (DAP)
they were ?5.22 (-13.50 to ?23.94) mmHg. These are
interesting and promising results and they suggest that
trending arterial blood pressure non-invasively via arterial
tonometry may be a reality. More studies are needed in
shocked patients, where often vasopressors are titrated
against absolute values of MAP; at the moment such
devices cannot be used as single blood pressure monitors.
Fluid replacement therapies and fluid responsiveness
This year in Intensive Care Medicine some papers and
reviews analyzed the problem of fluid replacement ther-
apies and indices of fluid responsiveness.
Response to fluid challenge is often defined as an
increase in cardiac index (CI) of more than 10–15 %.
However, in clinical practice CI values are often not
available. In an observational study Pierrakos et al. [59]
evaluated whether changes in MAP correlate with chan-
ges in CI after fluid challenge in patients with septic
shock. The authors analyzed data prospectively collected
from 51 septic shock patients, in whom complete hemo-
dynamic measurements had been obtained before and
after a fluid challenge with 1,000 ml crystalloid (Hart-
man’s solution) or 500 ml colloid (hydroxyethyl starch
(HES) 6). The authors divided the patients into two
groups (responders and non-responders) according to their
change in CI (responders: % CI greater than 10 %) after
the fluid challenge. The changes in MAP did not reliably
track changes in CI after fluid challenge and the conclu-
sion was that MAP should be interpreted carefully when
evaluating the response to fluid challenge in septic shock
patients.
In a study on the influence of the expiratory muscle
activity on end-expiratory CVP, Leatherman et al. [60]
showed that the changes in intra-abdominal pressure
(DIAP) in 39 patients who had a respiratory excursion in
CVP from end-expiration to end-inspiration (CVP(ee) -
CVP(ei)) of at least 8 mmHg, the CVP variations over-
estimated the transmural right atrial pressure. However
the authors showed also that the magnitude of expiratory
muscle activity can be assessed by measuring DIAP.
Subtracting DIAP from the end-expiratory CVP can pro-
vide a reasonable estimate of the CVP that would be
obtained if exhalation were passive.
Hydroxyethyl starch is a synthetic colloid used widely
for resuscitation despite the availability of safer, less
costly fluids. Hartog et al. [61] investigated the potential
reasons why HES use has become so widespread despite
what appears to be objective data challenging its benefit
and safety. They therefore examined the relationship
between the methodological quality of published HES
reviews, authors’ potential conflicts of interest (pCOI),
and the recommendations made. Between 1975 and 2010,
165 reviews were published containing recommendations
for or against HES use. From the 1990s onwards, favor-
able reviews increased from two to eight per year and
HES’s share of the artificial colloid market tripled from
20 to 60 %. Methodology was discussed to minimize the
ability of a select group of clinicians with undisclosed
industry ties to flood the scientific literature with low-
quality positive reviews and possibly affect sales of
products that may potentially increase patient risks. This
review stimulated an animated discussion.
Gelatin, a degradation product of collagen, is fre-
quently used as a volume expander in critical care.
Thomas-Rueddel et al. [62] aimed at investigating the
current clinical evidence on the safety of this product and
systematically reviewed the randomized controlled trials
(RCTs) in patients receiving gelatin for resuscitation in
comparison to albumin or crystalloids. A total of 40 RCTs
were published between 1976 and 2010 with 3,275
patients. Median sample size in the gelatin groups was 15
patients (range 10–249). Median gelatin dose was 17 ml/
kg (range 6–57 ml/kg). In 32 RCTs (n = 1,946/3,275,
59 % of all patients), the study period was 24.0 h at most.
Twenty-nine RCTs (n = 2,001) investigated elective
surgical patients, mostly undergoing cardiac surgery (18
RCTs, n = 819). Three RCTs (n = 723) investigated
critically ill adults. Two RCTs (n = 59) were performed
in emergency room patients, and six RCTs (n = 492)
were performed in neonates or children. No study was
adequately powered to investigate the frequency of
patient-important outcomes. Risks were not statistically
significantly different for mortality (RR 1.12, 95 % CI
0.87–1.44) and exposure to allogeneic transfusion (RR
1.28, 0.89–1.83). Only three RCTs reported the occur-
rence of acute renal failure. It was concluded that despite
over 60 years of clinical practice, the safety and efficacy
of gelatin cannot be reliably assessed in at least some
settings in which it is currently used.
Sandroni et al. [63] conducted a systematic review to
assess the accuracy of the variation in pulse oximetry
plethysmographic waveform amplitude (DPOP) and the
Pleth variability index (PVI) as predictors of fluid
responsiveness in mechanically ventilated adults. Ten
studies in 233 patients were included. All patients were in
normal sinus rhythm. The pooled area under the receiver
operating characteristic curve (AUC) for identification of
fluid responders was 0.85 (95 % CI 0.79–0.92). Pooled
sensitivity and specificity were 0.80 (95 % CI 0.74–0.85)
and 0.76 (0.68–0.82), respectively. No heterogeneity was
found within studies with the same amount of fluid bolus,
nor between studies on DPOP and those on PVI. The
AUC was significantly larger in studies with a large bolus
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amount than in those with a small bolus [0.92 (95 % CI
0.87–0.96) vs. 0.70 (0.62–0.79); p \ 0.0001]. Sensitivity
and specificity were also higher in studies with a large
bolus [0.84 (95 % CI 0.77–0.90) vs. 0.72 (0.60–0.82)
(small bolus), p = 0.08 and 0.86 (95 % CI 0.75–0.93) vs.
0.68 (0.56–0.77) (small bolus), p = 0.02], respectively.
The authors concluded that on the basis of their meta-
analysis, the DPOP and PVI are equally effective for
predicting fluid responsiveness in ventilated adult patients
in sinus rhythm. Prediction is more accurate when a large
fluid bolus is administered.
Inotropes and vasoactive agents
Dobutamine is recommended for patients with severe
heart failure and symptoms related to low CO and poor
tissue perfusion. However there is concern and uncer-
tainty regarding the harm–benefit balance associated with
its use in this population. Tacon et al. [64] conducted this
meta-analysis to evaluate whether dobutamine, compared
with placebo or standard care, is associated with lower
mortality and a range of secondary outcomes in patients
with severe heart failure. Randomized trials comparing
dobutamine with placebo or standard care, in human,
adult patients with severe heart failure, were included if
they reported at least one outcome of interest. Fourteen
studies, with 673 participants, met the inclusion criteria
and were included; 13 studies reported mortality. There
was minimal heterogeneity (I(2) = 4.5 %). The estimate
of the OR for mortality for patients with severe heart
failure treated with dobutamine compared with standard
care or placebo was 1.47 (95 % CI 0.98–2.21, p = 0.06).
The authors concluded that dobutamine is not associated
with improved mortality in patients with heart failure,
and there is a suggestion of increased mortality associ-
ated with its use, although this did not reach the
conventional level of statistical significance. It was also
pointed out that studies had a poor level of methodo-
logical reporting.
Vasopressin infusion was shown to improve hemo-
dynamic status in patients with vasodilatory shock, but
may have relevant clinical side effects and its effect on
mortality is controversial. Polito et al. [65] performed a
meta-analysis to examine the effects of vasopressin or its
analogue terlipressin on morbidity and mortality in
patients with vasodilatory shock. The primary outcome
for this meta-analysis was short-term all-cause mortality.
Six studies were considered for the main analysis on
mortality in adults. The crude short-term mortality was
206 of 512 (40.2 %) in vasopressin/terlipressin-treated
patients and 198 of 461 (42.9 %) in controls [six trials,
risk ratio (RR) = 0.91; 95 % CI 0.79–1.05; p = 0.21;
I(2) = 0 %]. There were 49 of 463 (10.6 %) patients with
serious adverse events in the vasopressin/terlipressin arm
and 51 of 431 (11.8 %) in the control arm (4 trials,
RR = 0.90; 95 % CI 0.49–1.67; p = 0.75; I(2) = 26 %).
It was concluded that the use of vasopressin or terlipressin
did not produce any survival benefit in the short term in
patients with vasodilatory shock.
Catecholamine vasopressor therapy in surgical ICU
patients with cardiovascular failure may produce adverse
cardiac events. Schmittinger et al. [66] investigated the
occurrence of any of seven predefined adverse cardiac
events (prolonged elevated heart rate, tachyarrhythmia,
myocardial cell damage, acute cardiac arrest or death,
pulmonary hypertension-induced right heart dysfunction,
reduction of systemic blood flow) during catecholamine
vasopressor therapy lasting at least 12 h.
New-onset tachyarrhythmia (49.1 %), prolonged ele-
vated heart rate (23.7 %), and myocardial cell damage
(17.5 %) occurred most frequently. Globally, adverse
cardiac events occurred in 44 (48.2 %) out of 112 of
surgical ICU patients with cardiovascular failure and were
related to morbidity and mortality. The extent and dura-
tion of catecholamine vasopressor therapy were
independently associated with and may contribute to the
pathogenesis of adverse cardiac events.
Organization, quality of care, and outcome
Medication errors are common in hospital. Opportunities
for errors are maximized in ICUs. One simple way to
limit errors in medication administration is to improve
color-coded drug labelling. ISO norm 26825 for color
drug labelling has been created in anesthesiology and
extended for use in intensive care and emergency medi-
cine. In a survey endorsed by ESICM, Balzer et al. [67]
found that only 35 % of the respondents reported that
standardized drug labelling was used hospital-wide, and
39 % reported that standardized drug syringe labelling
(DSL) was used in their ICU (Europe: Northern 53 %,
Western 52 %, Eastern 17 %, Southern 22 %). The ISO
norm 26825 was used by 30 %, an adapted version by
19 %, and local versions by 45 %. The improvement of
adherence to this simple norm should be an important tool
for decreasing medication errors.
Variability of critical care bed numbers in Europe has
been studied by Rhodes et al. [68]. Data were derived
from large international databases and validated by the
national council representative for the ESICM. In coun-
tries where data were still not available, personal contacts
were used and numbers were estimated according to local
sample assessment. They identified 409 acute care beds
and 11.5 critical care beds on average per 100,000
inhabitants. The rates per 100,000 inhabitants were
markedly different between countries: from 29.2 for
Germany, 12.5 for Italy, 11.6 for France, 9.7 for Spain, 6
for Greece, to 4.2 for Portugal. The rates of critical care
beds were correlated with percentage of gross domestic
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product dedicated to health expenditure with marked
differences between countries.
Recent studies conducted on ICU patients have shown
an advantage for patients treated in high volume centers
and some have shown benefit with the adoption of cen-
tralized services for ICUs as well. Kanhere et al. [69]
conducted a systematic review to assess if outcomes in
adult ICUs are related to hospital and ICU patient volume.
Twenty-five articles were relevant to this study. After
further evaluation a total of 13 studies including 596,259
patients across 1,068 ICUs met the inclusion criteria and
were reviewed. All were observational cohort studies.
Four of the studies included all admissions to ICU, five
included mechanically ventilated patients, two reported
on patients admitted with sepsis, and one study each
reported on patients admitted with medical diagnoses and
post-cardiac arrest patients admitted to ICU, respectively.
There was a wide variability in the quantitative definition
of volume and classification of hospitals and ICUs on this
basis. Methodological heterogeneity amongst the studies
precluded a formal meta-analysis. A trend towards
favorable outcomes for high volume centers was observed
in all studies. Risk-adjusted mortality rates revealed a
survival advantage for a specific group of patients in high
volume centers in ten studies but no significant difference
in outcomes was evident in three studies. It was con-
cluded that outcomes of certain subsets of ICU patients
(especially those on MV, high-risk patients, and patients
with severe sepsis) are better in high volume centers
within the constraints of risk adjustments.
Burnout syndrome (BOS) has frequently been reported
in health-care workers, and precipitating factors include
communication problems in the workplace and stress
related to end-of-life situations. In a before–after study,
Quenot et al. [70] evaluated the effect of an intensive
communication strategy on BOS among caregivers
working in ICU. The intervention was multifactorial, with
mixed changes in ward organization (including unre-
stricted visiting hours, fixed appointments with families,
staff psychologist availability) and in communication on
BOS strategy. They found a significant difference
between periods in all three components of the Maslach
Burnout Inventory (MBI) (emotional exhaustion,
p = 0.04; depersonalization, p = 0.04; personal accom-
plishment, p = 0.01). MBI classified burnout as severe in
15 (28 %) caregivers in period 1 versus 7 (14 %) in
period 2, p \ 0.01, hence a 50 % risk reduction. Symp-
toms of depression as evaluated by the CES-D were
present in 9 (17 %) caregivers in period 1 versus 3 (6 %)
in period 2, p \ 0.05, hence a risk reduction of almost
60 %. Further randomized trials focused on interventions
on communication factors are needed to confirm these
results.
Outcome and quality of life after ICU
The age distribution of the population may contribute to
the need for ICU beds to ensure the elderly beneficiate
from ICU stay. In a retrospective study based on a data-
base from the Beth Israel Diaconess Hospital in Boston,
Fuchs et al. [71] evaluated the 28-day and 1-year impact
of age while carefully taking into account comorbid
condition and severity of the patients. Patients were
divided into three age groups: 65–74, 75–84, and 85 and
above. The analysis focused on the 7,265 non-planned
admissions of patients above the age of 65 (45.7 % of the
total ICU population). From the first to third age group
there was an increased prevalence of cardiac comorbid
illnesses, but a reduced prevalence of diabetes compli-
cations (7.5–2.4 %), alcohol abuse (4.1–0.6 %),
metastatic cancer (8.3–3.6 %), chronic obstructive pul-
monary disease (COPD) (24.4–17.4 %), and liver failure
(5.0–1.0 %). Do not resuscitate order (DNRO) at admis-
sion increased from 6.8 % in the 65–74 age group to
15.4 % in the 75–84 group and 29.6 % in the 85 and over
group (p \ 0.001). Logistic regression analysis adjusted
for gender, SOFA, DNRO, and Elixhauser comorbidity
score found that patients from the second and third age
group had ORs of 1.38 (95 % CI 1.19–1.59) and 1.53
(95 % CI 1.29–1.81) for 28-day mortality as compared
with the first age group. Interestingly effect of age on the
1-year mortality was similar in the Cox regression anal-
ysis [75–84: adjusted hazard ratio 1.21 (95 % CI
1.06–1.38); 85 years and over: adjusted hazard ratio 1.59
(95 % CI 1.37–1.85)]. In conclusion, the effect of age
adjusted for confounders was linear, although there was a
non-significant modification in the slope of 1-year mor-
tality over 84 years.
The impact of the precocity of ICU intervention in the
prognosis of cancer patients is also an important matter of
interest. In a retrospective monocenter study from Korea,
Song et al. [72] studied the impact of an early intervention
of a medical emergency team (MET) on the prognosis of
cancer patients. They analyzed 199 critically ill cancer
patients admitted to the ICU for in-hospital mortality.
Median time from physiological derangement to inter-
vention (time to intervention) prior to ICU admission was
1.5 (IQR 0.6–4.3) h. Median time to intervention was
significantly shorter in survivors than in non-survivors
(0.9 vs. 3.0 h; p \ 0.001). Early intervention was asso-
ciated with a lower SOFA score. Independent of the
severity of illness, performance status, hematologic
malignancy, stem-cell transplantation, presence of three
or more abnormal physiological variables, presence of
infection, need for MV and vasopressor, and low PaO2/
FiO2 ratio, the time from derangement to ICU admission
was still significantly associated with hospital mortality
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(adjusted OR 1.45, 95 % CI 1.22–1.72). The retrospective
monocentric study argued for an early ICU admission of
cancer patients. Further prospective study prospectively
taking into account the reason for MET call, physician
belief, and lead time bias (SOFA was measured only
during MET intervention but not at the beginning of the
acute care process) is warranted to confirm and quantify
the effect.
Agitation and delirium are common in the critically ill.
Nicotine withdrawal has been identified as a contributing
factor to this. Nicotine replacement therapy may decrease
withdrawal and improve ICU delirium and outcome. But
nicotine replacement therapy was associated with an
increased hospital mortality in a retrospective case control
study likely owing to the sympathomimetic cardiovascu-
lar effect of nicotine. In a large retrospective cohort study
of 423 smokers, after careful adjustment for confounders,
and using various statistical models, Gillies et al. [73] did
not find any association between NRT and hospital mor-
tality. An RCT is therefore feasible to test the effect of
NRT on delirium and patients’ outcome.
Traumatic aortic injury is relatively infrequent but
associated with a subsequent mortality if therapeutic
management is delayed [74]. In a multicenter retrospec-
tive study involving 640 major trauma patients with
associated blunt chest trauma, 76 were associated with
aortic injury. They found that widened mediastinum,
hypotension less than 90 mmHg, long bone fracture,
pulmonary contusion, left scapula fracture, hemothorax,
and pelvic fracture were independently associated with
aortic injury. They proposed a risk score with an excellent
accuracy (AUC ROC curve 0.96). External multicenter
validation is needed to confirm this result.
It is important to decrease psychologic sequelae during
recovery. In a multicenter RCT, McKinley and co-workers
[75] studied the effect of physical rehabilitation on
depression, anxiety, stress, and quality of sleep. The authors
found that ICU survivors had impaired mental health and
symptoms of depression, anxiety, stress, and psychological
distress in the form of intrusive and avoidance post-trau-
matic stress symptoms. Anxiety symptoms persisted for
one quarter of the patients after 8 and 26 weeks. Although
physical rehabilitation did not decrease the psychological
sequelae, they found that female gender, early levels of
increased stress, and sleeping problems are associated with
worse psychological recovery.
Echography and imaging
An expert panel conference report provided evidence-
based consensus recommendations for lung ultrasound
with a focus on emergency and critical care settings [76].
A multidisciplinary panel of 28 experts from eight
countries was involved. The process used to develop these
evidence-based recommendations involved two phases:
determining the level of quality of evidence and devel-
oping the recommendation. The quality of evidence was
assessed by the grading of recommendation, assessment,
development, and evaluation (GRADE) method. How-
ever, the GRADE system does not enforce a specific
method on how the panel should reach decisions during
the consensus process. The methodology committee
decided to utilize the RAND appropriateness method for
panel judgment and decisions/consensus. Statements on
pneumothorax, interstitial syndrome (pneumonia, atelec-
tasis, pleural disease, etc.), monitoring of lung diseases
(cardiogenic pulmonary edema, lung reaeration in ARDS,
etc.), and neonatal and pediatric pulmonary problems
were produced. It was concluded that the document was
elaborated to guide implementation, development, and
training on the use of lung ultrasound in all relevant
settings.
Another group of experts provided recommendations
on ultrasound guidance during vascular access [77]. Also
these authors used the GRADE and the GRADE-RAND
methods to develop recommendations. The recommen-
dations suggest the advantage of 2D vascular screening
prior to cannulation and that real-time ultrasound needle
guidance with an in-plane/long-axis technique optimizes
the probability of needle placement. Ultrasound guidance
can be used not only for central venous cannulation but
also in peripheral and arterial cannulation. Ultrasound can
be used in order to check for immediate and life-threat-
ening complications as well as the catheter’s tip position.
Educational courses and training are required to achieve
competence and minimal skills when cannulation is per-
formed with ultrasound guidance. This technique allows
the reduction of infectious and mechanical complications.
A recommendation to create an ultrasound curriculum on
vascular access was proposed. It was concluded that given
the evidence from literature and experts’ opinion, ultra-
sound guidance has to be suggested as the method of
choice for any kind of vascular cannulation given its
higher safety and efficacy.
A review article discusses technical requirements for
Doppler assessment of the small intra-renal vessels, fac-
tors influencing Doppler-based renal resistive index (RI),
and to provide an updated description of its interest with a
special focus on the critically ill [78]. Data suggest that
renal Doppler may help to assess perfusion of native or
transplanted kidneys, and recent studies suggest that it
may be useful in critically ill patients. Renal Doppler has
proven to be valuable for assessing large arterial or
venous abnormalities and has been suggested to assess
renal perfusion and to predict AKI in critically ill patients.
However, numerous factors have been shown to influence
renal Doppler and may constitute potential confounding
factors. It was concluded that Doppler-based RI seems to
be a promising tool in the critically ill to assess the risk of
AKI, help in differentiating persistent from transient AKI,
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or assess changes in renal perfusion as consequences of
therapeutic intervention. The authors also pointed out that
the role of renal Doppler as a monitoring tool in the ICU
will remain unclear until additional studies are conducted
and the potential confounding factors are properly
assessed.
Lakhal et al. [79] analyzed the current practices of
chest radiograph (CXR) prescription and their clinical
impact in French ICUs with a prospective snapshot
observational study (on RadioDay) combined with a
survey. On RadioDay, 854 CXRs (in 804 patients) were
ordered. For the ‘‘CXRs morning round’’, the prescription
policy was declared to be ‘‘on-demand’’ (in 63 % of the
ICUs), ‘‘daily routine only in mechanically ventilated
patients (MV)’’ (30 %) or, less frequently, ‘‘daily routine
in all patients’’ (7 %). When analyzing the two main local
policies, as compared with ‘‘daily routine only in MV’’
ICUs, in ‘‘on-demand’’ ICUs: (1) fewer CXRs were
ordered (0.6 ± 0.3 vs. 0.9 ± 0.2 CXRs/patient,
p \ 0.001) with no increase in the rate of unscheduled
CXRs (i.e., CXRs performed outside the morning round),
and (2) individual CXRs were more often followed by a
therapeutic intervention (which would not have occurred
without the CXR): 34 vs. 25 % of the CXRs (p \ 0.05).
Nearly two-thirds of the participating ICUs adopted the
‘‘on-demand’’ strategy of prescription, which was asso-
ciated with a lower rate of CXRs with no increase in
unscheduled CXRs and was of higher clinical value than a
‘‘daily routine in MV’’ strategy.
Rohacek et al. [80] performed a prospective survey
among the emergency physicians on the reason for
ordering a CT pulmonary angiography (CTPA) in the
emergency room. The most frequent reasons for ordering
a CTPA were to confirm/rule out pulmonary embolism
(PE) (93 %), elevated D-dimers (66 %), fear of missing
PE (55 %), and Wells/simplified revised Geneva score
(53 %). Interestingly, a positive answer for ‘‘fear of
missing PE’’ was inversely associated with positive
CTPA (OR 0.36, 95 % CI 0.14–0.92, p = 0.033), and
‘‘Wells/simplified revised Geneva score’’ was associated
with positive CTPA (OR 3.28, 95 % CI 1.24–8.68,
p = 0.017). The proportion of positive CTPA was higher
if a questionnaire was completed (26.4 vs. 14.5 %, OR
2.12, 95 % CI 1.36–3.29, p \ 0.001).
Ethics and legal section
In the past year, Intensive Care Medicine has published a
number of important articles in the ‘‘Ethics and Legal
Section’’ that have addressed a diverse group of topics
including the ethics of clinical research in the ICU, the
provision of end-of-life care in the ICU, and the impact of
intensive care on the emotional and psychological health
of ICU clinicians.
Ethics of clinical research in end-of-life care
There has been increasing interest in examining the ethics
of conduct of clinical research in the ICU. Critically ill
patients and their family members represent a vulnerable
population for research and it is important that we protect
this vulnerable group. At the same time, delivery of high-
quality care requires clinical research to ensure that we
understand which therapies and approaches are most
effective and that we implement these therapies and
approaches in an efficient and timely way. Barrett and
colleagues [81] performed a cross-sectional study of the
attitudes of surrogate decision-makers toward research
decision-making for critically ill patients. They presented
136 surrogate decision-makers of critically ill patients in
five ICUs in Canada with four different hypothetical
research scenarios during a structured interview. The four
research scenarios included a placebo-controlled RCT, a
study with higher risk of treatment complication, a study
comparing two accepted treatments, and a study with a
short enrolment window. They found that 90 % of par-
ticipants wished to be involved in research decision-
making and participants’ responses varied little across the
different hypothetical studies. Eighty-five percent of
participants considered their involvement in the consent
process to be acceptable, but the proportion decreased
when risk of harm was higher or the enrolment window
was shorter. These authors did not find an association
between attitudes toward participation in research and
levels of symptoms of anxiety and depression. Specific
suggestions to improve the consent process endorsed by
the majority surrogate decision-makers included having
the consent process preceded by a medical update from
the ICU physician, having the ICU physician involved in
the research decision-making process, having a discussion
about the research in a private setting, and providing more
verbal information than is generally given.
A single-center study from Canada by Mehta and
colleagues [82] used questionnaires to explore the reasons
that surrogate decision-makers agreed or declined to
participate in one of a series of studies concerning criti-
cally ill patients. The questionnaires explored surrogate
decision-makers’ opinions about research in general,
timing of research approach, the informed consent pro-
cess, and reasons for agreeing or declining participation.
The investigators enrolled 96 surrogate decision-makers
including 68 who agreed to participation in an ICU study
and 27 who declined participation. There were no dif-
ferences between the two groups with respect to
demographics, perceived severity of illness of the patient,
or the research study approach. The most common rea-
sons for providing consent were potential for research to
help others, research being important for medical pro-
gress, and trust in the medical team. The most common
reasons for declining consent were that the surrogate
decision-maker was too anxious to consider research, fear
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that the patient would receive experimental treatment, and
concern about risks of the study. This study also suggests
that having two or more family members involved in the
consent process may help family members with the stress
of considering research and could enhance research
participation.
Menon and colleagues examined consent rates in
pediatric critical care research and the association
between consent rates and multiple factors including
patient, legal guardian, consent process, and study design-
related factors. They conducted a prospective cohort
study in six pediatric ICUs in Canada with legal guardians
of patients who were approached for consent for any
research study. They recorded 271 consent encounters.
The overall consent rate was 80 % and they observed
higher consent rates when research assistants were intro-
duced to the family by a member of the clinical team.
Interestingly, there was no difference in consent rates
between therapeutic versus non-therapeutic studies. This
study suggests researchers should consider routine intro-
duction of the research assistant to the family by a
member of the patient’s care team.
Influence of physician attitudes and education
and of ICU culture on end-of-life decision-making
There were three interesting articles in 2012 that exam-
ined the role of physicians and ICU culture on end-of-life
decision-making. Schenker and colleagues [83] examined
the association between physicians’ beliefs and the pre-
sentation to the family of the option of comfort care for
critically ill patients. This was a mixed-methods study of
72 audio-recorded family conferences about treatment
decisions in ICUs at two hospitals in San Francisco, CA.
The family conferences concerned patients at high risk of
death or severe functional impairment and 72 % died
during this hospitalization. A total of 169 family members
and 54 physicians participated. The authors examined the
audio-recorded conferences to identify whether physi-
cians offered comfort care as an alternative to life-
sustaining treatment. Physicians completed a question-
naire indicating the strength of their belief that life
support should be foregone. Using a broad definition of
comfort-oriented treatment, Schenker and colleagues
found that this option was presented in 56 % of confer-
ences. The only independent predictor of offering comfort
care as an option was the strength of the physician’s belief
that life support should be foregone, suggesting that a
physician’s belief that the appropriate goal of care is life
prolongation may result in inappropriately withholding
the option of comfort care from some patients and their
family members.
A study by Forte and colleagues [84] from Brazil
examined the association between physician education in
end-of-life care and variability in clinical practice. The
authors surveyed physicians from 11 ICUs at a university
hospital concerning a hypothetical patient in a vegetative
state with no family or advance directives. They obtained a
response rate was 89 %, with 105 questionnaires analyzed.
They found that physicians who did not apply DNROs were
less likely to have attended classes on end-of-life care. They
found that physicians who would apply ‘‘full code’’ to the
hypothetical patient had less often read about end-of-life
care and had less interest in discussing end-of-life care with
colleagues. These results demonstrate that education in end-
of-life care is associated with physician self-reported
practice patterns regarding end-of-life care.
A unique study by Barnato and colleagues [85] exam-
ined the norms of decision-making in the ICUs of two
academic medical centers in one city that represented the
two extremes in intensity of care at the end-of-life. The
authors conducted a 4-week mixed-methods case study at
each medical center involving direct observation of patient
care during rounds in the main medical ICU, semi-struc-
tured interviews with staff, patients, and families, and
collection of materials such as patient lists and standardized
forms. They compared patterns of decision-making
regarding initiation, continuation, and withdrawal of life
support using qualitative research methods. They observed
80 patients cared for by 4 senior physicians at the low-
intensity medical center and observed 73 patients cared for
by 4 senior physicians at the high-intensity medical center.
Life support initiation was similar, but the low-intensity
medical center was more likely to use a time-limited trial of
life support, followed by withdrawal of life support. They
also identified important differences between the two
medical centers in the ultimate goals of life support, the
determination of when a patient is considered to be ‘‘dying’’,
a focus on concerns about harms of commission versus
omission, and physician self-efficacy for life support deci-
sion-making. This study highlights some of the differences
in the medical culture between ICUs that provide high-
intensity care at the end of life compared to those that pro-
vide low-intensity care at the end of life.
Provision of end-of-life care in the ICU
There were two interesting studies about the provision of
end-of-life care in the ICU. In the first, Azoulay and
colleagues [86] examined whether patients who had a
birthday during their ICU stay seemed to a receive dif-
ferent level of care than those who did not. They
conducted a case–control design in which patients
spending their birthday in the ICU (cases) were matched
to controls in terms of hospital, gender, age, severity of
illness, and type of admission. The study was conducted
in 12 ICUs in French hospitals. They found that compared
with controls, the cases were more often trauma patients
and received a larger number and longer durations of life-
sustaining interventions. This increased intensity of life
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support occurred after, but not before, the birthday. The
cases had longer ICU stays, although ICU and hospital
mortality were not different between the two groups.
Decisions to limit life support were made in the same
proportion in both groups (22 and 24 % of cases and
controls, respectively), but these decisions were made
significantly later in the cases than in the controls.
Although the reasons for this association are not clear, the
study suggests that patients who spent their birthday in the
ICU were more likely to receive non-beneficial
interventions.
In the second study, Bulow and colleagues [87]
examined differences in decisions about end-of-life care
and respect for patient autonomy across different religions
and religiosity. They examined results of structured
questionnaires regarding decisions about end-of-life care
that were completed in six European countries in 142
ICUs. This study focused on responses from Protestants,
Catholics, and Jews, the largest categories of religions in
the sample. They examined a total of 304 physicians, 386
nurses, 248 patients, and 330 family members, finding
that professionals wanted less treatment for themselves
(ICU admission, CPR, ventilator treatment) than did
patients and family members. Respondents reporting
higher religiosity (defined by self-report as ‘‘religious’’ or
‘‘very religious’’) wanted more treatment and were more
in favor of life prolongation. There were no differences
between religions and religiosity regarding patient’s
autonomy. However, Protestants were more likely to
report the importance of following competent patients’
wishes and the Jewish respondents least likely to do so.
Jewish professionals more frequently accepting patients’
wishes for futile treatment. This study adds to the litera-
ture that examines the influence of religion and religiosity
on patient, family, and health-care professionals’ attitudes
toward end-of-life care.
Regional studies of end-of-life care in the ICU
There were several studies that examined end-of-life care
or triage decisions in different countries. In a study from
France, Quenot and colleagues [88] examined the impact
of a communication strategy on end-of-life care in the
ICU after passage of a 2005 French law pertaining to the
family’s role in decision-making for critically ill patients.
The authors examined whether an intensive communica-
tion strategy based on this law would influence practices
in terms of withholding and withdrawing treatment and
patient outcome. They conducted a single-center, two-
period study performed before and after the 2005 French
law (a law specifying new patient and family member
rights regarding end-of-life care) using data obtained from
the medical record. Between these periods, an intensive
strategy for communication was developed and imple-
mented, comprising regular meetings and specific changes
in the organization of the ICU with regard to family
communication and approaches to communication with
families (such as increased family visiting hours). Of
2,478 patients admitted in period 1, 27 % died in the ICU
compared to 28 % in period 2. In period 1, among
patients who died in the ICU, 45 % died subsequent to a
decision to withhold or withdraw life support versus a
significantly higher 85 % in period 2. The median time
delay between ICU admission and initiation of decision-
making process was significantly shorter in period 2 (6–7
vs. 3–5 days). Similarly, median time from admission to a
decision to withhold or withdraw life support was sig-
nificantly shorter in period 2 (11–13 vs. 4–6 days). In
addition, median time from admission to death in the ICU
after a decision to withhold or withdraw life support was
significantly shorter in period 2. The reasons documented
for withholding or withdrawing life support were not
significantly different between periods. This study sug-
gests that an intensive communication in combination
with a new law increasing family members’ role in
decision-making was associated with faster decision-
making about end-of-life care in the ICU.
There were also two studies examining ICU care in
developing countries, about which there has been little
research. In the first, Ouanes and colleagues [89] examined
decisions about end-of-life care in two Tunisian ICUs. The
authors examined consecutive deaths that occurred in a
medical and a surgical ICU in one hospital over 2 years.
Decisions about end-of-life decisions were prospectively
recorded by the senior attending physicians. They found
that 326 of 1,733 patients died (19 %). A decision for full
support was made in 69 %, whereas decisions to withhold or
withdraw life support were made in 22 and 9 % of deaths,
respectively. The decisions about end-of-life care were
similar in the medical and surgical ICUs. There was no
instance of withdrawal of MV. Of the 20 patients who died
after withdrawal of life support in the medical ICU, 10
patients were discharged to die at home. Two factors were
independently associated with decisions to withhold or
withdraw life support: a severe and ultimately fatal under-
lying disease and the absence of independent functional
status before the ICU. The authors conclude that with-
holding and withdrawing life support are common in
medical and surgical ICUs of a Tunisian hospital.
In the second, Louriz and colleagues [90] examined
the determinants and outcomes associated with decisions
to deny or delay ICU admission to a medical ICU in
Morocco. Over a 6-month period, ICU admission was
requested for 398 patients: 28 % were immediately
admitted, 36 % were never admitted, and 36 % were
admitted at a later time. The reasons for refusal included
too sick to benefit (11 %), too well to benefit (19 %), unit
full (41 %), and more patient data needed to make a
decision (30 %). Predictors of ICU refusal for never-
admitted patients included severity of acute illness and
lack of available ICU beds. Hospital mortality was lowest
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for immediately admitted patients at 33 % and higher for
patients admitted later (44 %) and for never-admitted
patients (49 %).
Gristina and colleagues [91] published a commentary
addressing the limitations of a proposed new Italian reg-
ulation concerning advance directives. In Italy, the role of
advance directives has recently been the subject of debate
involving political parties and the Roman Catholic
Church. In February 2009, a government coalition pre-
sented a bill of law on this issue that has been passed by
the Lower Chamber. The authors’ goal in this commen-
tary is to highlight the bill’s contradiction with Italian
Constitution, Italian Code of Medical Ethics (ICME), and
Oviedo Convention contents through an analysis of the
bill’s content in the light of these articles and by com-
parison with French legislation regarding end of life
(Leonetti law). The authors conclude that advance
directives should represent informed preferences made
freely by patients within the relationship with their phy-
sicians, as part of an advance care planning. They further
conclude that the law should be revised to meet ICME
principles, assigning advance directives a juridical power,
acknowledging their validity in legitimating end-of-life
decisions, and defining a framework of juridical legiti-
macy for these decisions without infringing on patients’
right to autonomy regarding health care.
Role of patient’s socioeconomic status, and predictors
of resilience in ICU clinicians
Two additional studies examined interesting aspects of
the delivery of intensive care. Few studies have examined
the role of socioeconomic status (SES) on care for criti-
cally ill patients, especially focusing on the surgical ICU.
Bein and colleagues [92] examined whether SES was
associated with the severity of illness at admission, length
of stay, and level of family member involvement in an
adult surgical ICU. This was a cohort study of 1,006
patients at a 24-bed surgical ICU in Germany. They found
that patients with low SES had higher severity of illness,
defined by the SOFA score, at admission as compared
with patients with high SES. When compared with men
with high SES, those with low SES were more likely to
receive ICU treatment for at least 5 days and showed a
trend for a lower number of visits from family. Similar
trends were not identified in women.
Mealer and colleagues [93] conducted a qualitative
study of resilience and post-traumatic stress disorder
(PTSD) among ICU nurses in the USA. The goal of the
study was to identify mechanisms employed by highly
resilient ICU nurses to provide insights into potential
preventative therapies to obviate the development of
PTSD in ICU nurse. They conducted a qualitative study
using semi-structured telephone interviews with randomly
selected ICU nurses in the USA. Purposive sampling was
used to identify ICU nurses who were highly resilient
based on a validated scale of resilience and those whose
score on a validated post-traumatic diagnostic scale was
consistent with a diagnosis of PTSD. The authors used a
constructivist epistemological framework for data analy-
sis. Highly resilient nurses identified spirituality, a
supportive social network, optimism, and having a resil-
ient role model as characteristics used to cope with stress
in their work environment. ICU nurses with a diagnosis of
PTSD possessed several unhealthy characteristics
including a poor social network, lack of identification
with a role model, disruptive thoughts, regret, and lost
optimism. These characteristics and skills may be used to
develop target therapies to prevent PTSD in ICU nurses.
References
1. Jones SA (2005) Directing transition
from innate to acquired immunity:
defining a role for IL-6. J Immunol
175:3463–3468
2. Martin-Loeches I, Sole-Violan J,
Rodriguez de Castro F, Garcia-Laorden
MI, Borderias L, Blanquer J, Rajas O,
Briones ML, Aspa J, Herrera-Ramos E,
Marcos-Ramos JA, Sologuren I,
Gonzalez-Quevedo N, Ferrer-Aguero
JM, Noda J, Rodriguez-Gallego C
(2012) Variants at the promoter of the
interleukin-6 gene are associated with
severity and outcome of pneumococcal
community-acquired pneumonia.
Intensive Care Med 38:256–262
3. van Delden C, Kohler T, Brunner-
Ferber F, Francois B, Carlet J, Pechere
JC (2012) Azithromycin to prevent
Pseudomonas aeruginosa ventilator-
associated pneumonia by inhibition of
quorum sensing: a randomized
controlled trial. Intensive Care Med
38:1118–1125
4. Azoulay E, Timsit JF, Tafflet M, de
Lassence A, Darmon M, Zahar JR,
Adrie C, Garrouste-Orgeas M, Cohen
Y, Mourvillier B, Schlemmer B (2006)
Candida colonization of the respiratory
tract and subsequent pseudomonas
ventilator-associated pneumonia. Chest
129:110–117
5. Roux D, Gaudry S, Dreyfuss D, El-
Benna J, de Prost N, Denamur E,
Saumon G, Ricard JD (2009) Candida
albicans impairs macrophage function
and facilitates Pseudomonas aeruginosa
pneumonia in rat. Crit Care Med
37:1062–1067
6. Hamet M, Pavon A, Dalle F, Pechinot
A, Prin S, Quenot JP, Charles PE (2012)
Candida spp. airway colonization could
promote antibiotic-resistant bacteria
selection in patients with suspected
ventilator-associated pneumonia.
Intensive Care Med 38:1272–1279
7. Ricard JD, Roux D (2012) Candida
colonization in ventilated ICU patients:
no longer a bystander! Intensive Care
Med 38:1243–1245
360
8. Jabre P, Combes X, Lapostolle F,
Dhaouadi M, Ricard-Hibon A, Vivien
B, Bertrand L, Beltramini A, Gamand
P, Albizzati S, Perdrizet D, Lebail G,
Chollet-Xemard C, Maxime V, Brun-
Buisson C, Lefrant JY, Bollaert PE,
Megarbane B, Ricard JD, Anguel N,
Vicaut E, Adnet F (2009) Etomidate
versus ketamine for rapid sequence
intubation in acutely ill patients: a
multicentre randomised controlled trial.
Lancet 374:293–300
9. Asehnoune K, Mahe PJ, Seguin P, Jaber
S, Jung B, Guitton C, Chatel-Josse N,
Subileau A, Tellier AC, Masson F,
Renard B, Malledant Y, Lejus C,
Volteau C, Sebille V, Roquilly A
(2012) Etomidate increases
susceptibility to pneumonia in trauma
patients. Intensive Care Med
38:1673–1682
10. Roquilly A, Mahe PJ, Seguin P, Guitton
C, Floch H, Tellier AC, Merson L,
Renard B, Malledant Y, Flet L, Sebille
V, Volteau C, Masson D, Nguyen JM,
Lejus C, Asehnoune K (2011)
Hydrocortisone therapy for patients
with multiple trauma: the randomized
controlled HYPOLYTE study. JAMA
305:1201–1209
11. Athanassa ZE, Markantonis SL,
Fousteri MZ, Myrianthefs PM,
Boutzouka EG, Tsakris A, Baltopoulos
GJ (2012) Pharmacokinetics of inhaled
colistimethate sodium (CMS) in
mechanically ventilated critically ill
patients. Intensive Care Med
38:1779–1786
12. Niederman MS, Chastre J, Corkery K,
Fink JB, Luyt CE, Garcia MS (2012)
BAY41-6551 achieves bactericidal
tracheal aspirate amikacin
concentrations in mechanically
ventilated patients with Gram-negative
pneumonia. Intensive Care Med
38:263–271
13. Croxen MA, Finlay BB (2010)
Molecular mechanisms of Escherichia
coli pathogenicity. Nat Rev Microbiol
8:26–38
14. Messika J, Magdoud F, Clermont O,
Margetis D, Gaudry S, Roux D, Branger
C, Dreyfuss D, Denamur E, Ricard JD
(2012) Pathophysiology of Escherichia
coli ventilator-associated pneumonia:
implication of highly virulent
extraintestinal pathogenic strains.
Intensive Care Med 38:2007–2016
15. Ayala E, Kagawa FT, Wehner JH, Tam
J, Upadhyay D (2009) Rhabdomyolysis
associated with 2009 influenza
A(H1N1). JAMA 302:1863–1864
16. Borgatta B, Perez M, Rello J, Vidaur L,
Lorente L, Socias L, Pozo JC, Pozo J,
Garnacho-Montero J (2012) Elevation
of creatine kinase is associated with
worse outcomes in 2009 pH1N1
influenza A infection. Intensive Care
Med 38:1152–1161
17. Wauters J, Baar I, Meersseman P,
Meersseman W, Dams K, De Paep R,
Lagrou K, Wilmer A, Jorens P,
Hermans G (2012) Invasive pulmonary
aspergillosis is a frequent complication
of critically ill H1N1 patients: a
retrospective study. Intensive Care Med
38:1761–1768
18. Annane D, Antona M, Lehmann B,
Kedzia C, Chevret S (2012) Designing
and conducting a randomized trial for
pandemic critical illness: the 2009
H1N1 influenza pandemic. Intensive
Care Med 38:29–39
19. Razazi K, Derde LP, Verachten M,
Legrand P, Lesprit P, Brun-Buisson C
(2012) Clinical impact and risk factors
for colonization with extended-
spectrum beta-lactamase-producing
bacteria in the intensive care unit.
Intensive Care Med 38:1769–1778
20. Tabah A, Koulenti D, Laupland K,
Misset B, Valles J, Bruzzi de Carvalho
F, Paiva JA, Cakar N, Ma X, Eggimann
P, Antonelli M, Bonten MJ, Csomos A,
Krueger WA, Mikstacki A, Lipman J,
Depuydt P, Vesin A, Garrouste-Orgeas
M, Zahar JR, Blot S, Carlet J, Brun-
Buisson C, Martin C, Rello J,
Dimopoulos G, Timsit JF (2012)
Characteristics and determinants of
outcome of hospital-acquired
bloodstream infections in intensive care
units: the EUROBACT International
Cohort Study. Intensive Care Med
38:1930–1945
21. Timsit JF, L’Heriteau F, Lepape A,
Francais A, Ruckly S, Venier AG, Jarno
P, Boussat S, Coignard B, Savey A
(2012) A multicentre analysis of
catheter-related infection based on a
hierarchical model. Intensive Care Med
38:1662–1672
22. Hermite L, Quenot JP, Nadji A, Barbar
SD, Charles PE, Hamet M, Jacquiot N,
Ghiringhelli F, Freysz M (2012)
Sodium citrate versus saline catheter
locks for non-tunneled hemodialysis
central venous catheters in critically ill
adults: a randomized controlled trial.
Intensive Care Med 38:279–285
23. Leon C, Ruiz-Santana S, Saavedra P,
Castro C, Ubeda A, Loza A, Martin-
Mazuelos E, Blanco A, Jerez V, Ballus
J, Alvarez-Rocha L, Utande-Vazquez
A, Farinas O (2012) Value of beta-D-
glucan and Candida albicans germ tube
antibody for discriminating between
Candida colonization and invasive
candidiasis in patients with severe
abdominal conditions. Intensive Care
Med 38:1315–1325
24. Matthaiou DK, Ntani G, Kontogiorgi
M, Poulakou G, Armaganidis A,
Dimopoulos G (2012) An ESICM
systematic review and meta-analysis of
procalcitonin-guided antibiotic therapy
algorithms in adult critically ill patients.
Intensive Care Med 38:940–949
25. Derde LP, Dautzenberg MJ, Bonten MJ
(2012) Chlorhexidine body washing to
control antimicrobial-resistant bacteria
in intensive care units: a systematic
review. Intensive Care Med 38:931–939
26. Silvestri L, de la Cal MA, van Saene
HK (2012) Selective decontamination
of the digestive tract: the mechanism of
action is control of gut overgrowth.
Intensive Care Med 38:1738–1750
27. Backes Y, van der Sluijs KF, Mackie
DP, Tacke F, Koch A, Tenhunen JJ,
Schultz MJ (2012) Usefulness of
suPAR as a biological marker in
patients with systemic inflammation or
infection: a systematic review.
Intensive Care Med 38:1418–1428
28. Dunser MW, Festic E, Dondorp A,
Kissoon N, Ganbat T, Kwizera A,
Haniffa R, Baker T, Schultz MJ (2012)
Recommendations for sepsis
management in resource-limited
settings. Intensive Care Med
38:557–574
29. Eisen DP (2012) Manifold beneficial
effects of acetyl salicylic acid and
nonsteroidal anti-inflammatory drugs
on sepsis. Intensive Care Med
38:1249–1257
30. Hicks CW, Sweeney DA, Cui X, Li Y,
Eichacker PQ (2012) An overview of
anthrax infection including the recently
identified form of disease in injection
drug users. Intensive Care Med
38:1092–1104
31. Massion PB, Peters P, Ledoux D,
Zimermann V, Canivet JL, Massion PP,
Damas P, Gothot A (2012) Persistent
hypocoagulability in patients with
septic shock predicts greater hospital
mortality: impact of impaired thrombin
generation. Intensive Care Med
38:1326–1335
32. Heilmann C, Geisen U, Beyersdorf F,
Nakamura L, Benk C, Trummer G,
Berchtold-Herz M, Schlensak C, Zieger
B (2012) Acquired von Willebrand
syndrome in patients with
extracorporeal life support (ECLS).
Intensive Care Med 38:62–68
361
33. Schaden E, Metnitz PG, Pfanner G,
Heil S, Pernerstorfer T, Perger P,
Schoechl H, Fries D, Guetl M, Kozek-
Langenecker S (2012) Coagulation Day
2010: an Austrian survey on the routine
of thromboprophylaxis in intensive
care. Intensive Care Med 38:984–990
34. Cheng SS, Nordenholz K, Matero D,
Pearlman N, McCarter M, Gajdos C,
Hamiel C, Baer A, Luzier E, Tran ZV,
Olson T, Queensland K, Lutz R,
Wischmeyer P (2012) Standard
subcutaneous dosing of unfractionated
heparin for venous thromboembolism
prophylaxis in surgical ICU patients
leads to subtherapeutic factor Xa
inhibition. Intensive Care Med
38:642–648
35. Dellinger RP, Levy MM, Carlet JM,
Bion J, Parker MM, Jaeschke R,
Reinhart K, Angus DC, Brun-Buisson
C, Beale R, Calandra T, Dhainaut JF,
Gerlach H, Harvey M, Marini JJ,
Marshall J, Ranieri M, Ramsay G,
Sevransky J, Thompson BT, Townsend
S, Vender JS, Zimmerman JL, Vincent
JL (2008) Surviving Sepsis Campaign:
international guidelines for
management of severe sepsis and septic
shock: 2008. Intensive Care Med
34:17–60
36. Rivers E, Nguyen B, Havstad S, Ressler
J, Muzzin A, Knoblich B, Peterson E,
Tomlanovich M (2001) Early goal-
directed therapy in the treatment of
severe sepsis and septic shock. N Engl J
Med 345:1368–1377
37. Jones AE, Shapiro NI, Trzeciak S,
Arnold RC, Claremont HA, Kline JA,
Emergency Medicine Shock Research
Network Investigators (2010) Lactate
clearance vs central venous oxygen
saturation as goals of early sepsis
therapy: a randomized clinical trial.
JAMA 303:739–746
38. De Backer D, Ospina-Tascon G,
Salgado D, Favory R, Creteur J,
Vincent JL (2010) Monitoring the
microcirculation in the critically ill
patient: current methods and future
approaches. Intensive Care Med
36:1813–1825
39. Myers DE, Anderson LD, Seifert RP,
Ortner JP, Cooper CE, Beilman GJ,
Mowlem JD (2005) Noninvasive
method for measuring local hemoglobin
oxygen saturation in tissue using wide
gap second derivative near-infrared
spectroscopy. J Biomed Opt 10:034017
40. Payen D, Luengo C, Heyer L, Resche-
Rigon M, Kerever S, Damoisel C,
Losser MR (2009) Is thenar tissue
hemoglobin oxygen saturation in septic
shock related to macrohemodynamic
variables and outcome? Crit Care
13(Suppl 5):S6
41. Creteur J, Carollo T, Soldati G, Buchele
G, De Backer D, Vincent JL (2007) The
prognostic value of muscle StO2 in
septic patients. Intensive Care Med
33:1549–1556
42. Georger JF, Hamzaoui O, Chaari A,
Maizel J, Richard C, Teboul JL (2010)
Restoring arterial pressure with
norepinephrine improves muscle tissue
oxygenation assessed by near-infrared
spectroscopy in severely hypotensive
septic patients. Intensive Care Med
36:1882–1889
43. Mesquida J, Espinal C, Gruartmoner G,
Masip J, Sabatier C, Baigorri F, Pinsky
MR, Artigas A (2012) Prognostic
implications of tissue oxygen saturation
in human septic shock. Intensive Care
Med 38:592–597
44. Lima A, van Genderen ME, Klijn E,
Bakker J, van Bommel J (2012)
Peripheral vasoconstriction influences
thenar oxygen saturation as measured
by near-infrared spectroscopy. Intensive
Care Med 38:606–611
45. Lima A, Jansen TC, van Bommel J,
Ince C, Bakker J (2009) The prognostic
value of the subjective assessment of
peripheral perfusion in critically ill
patients. Crit Care Med 37:934–938
46. Kaplan LJ, McPartland K, Santora TA,
Trooskin SZ (2001) Start with a
subjective assessment of skin
temperature to identify hypoperfusion
in intensive care unit patients. J Trauma
50:620–627 (discussion 627–628)
47. Bartels SA, Bezemer R, de Vries FJ,
Milstein DM, Lima A, Cherpanath TG,
van den Meiracker AH, van Bommel J,
Heger M, Karemaker JM, Ince C (2011)
Multi-site and multi-depth near-infrared
spectroscopy in a model of simulated
(central) hypovolemia: lower body
negative pressure. Intensive Care Med
37:671–677
48. Ait-Oufella H, Joffre J, Boelle PY,
Galbois A, Bourcier S, Baudel JL,
Margetis D, Alves M, Offenstadt G,
Guidet B, Maury E (2012) Knee area
tissue oxygen saturation is predictive of
14-day mortality in septic shock.
Intensive Care Med 38:976–983
49. Brown KA, Brain SD, Pearson JD,
Edgeworth JD, Lewis SM, Treacher DF
(2006) Neutrophils in development of
multiple organ failure in sepsis. Lancet
368:157–169
50. Buras JA, Reenstra WR (2007)
Endothelial-neutrophil interactions
during ischemia and reperfusion injury:
basic mechanisms of hyperbaric
oxygen. Neurol Res 29:127–131
51. Bertuglia S, Colantuoni A (2000)
Protective effects of leukopenia and
tissue plasminogen activator in
microvascular ischemia-reperfusion
injury. Am J Physiol Heart Circ Physiol
278:H755–H761
52. Karvunidis T, Chvojka J, Lysak D,
Sykora R, Krouzecky A, Radej J,
Novak I, Matejovic M (2012) Septic
shock and chemotherapy-induced
cytopenia: effects on microcirculation.
Intensive Care Med 38:1336–1344
53. Guyton AC (1955) Determination of
cardiac output by equating venous
return curves with cardiac response
curves. Physiol Rev 35:123–129
54. Maas JJ, Pinsky MR, Geerts BF, de
Wilde RB, Jansen JR (2012) Estimation
of mean systemic filling pressure in
postoperative cardiac surgery patients
with three methods. Intensive Care Med
38:1452–1460
55. Maas JJ, Geerts BF, van den Berg PC,
Pinsky MR, Jansen JR (2009)
Assessment of venous return curve and
mean systemic filling pressure in
postoperative cardiac surgery patients.
Crit Care Med 37:912–918
56. Pirracchio R, Cholley B, De Hert S,
Solal AC, Mebazaa A (2007) Diastolic
heart failure in anaesthesia and critical
care. Br J Anaesth 98:707–721
57. Mahjoub Y, Benoit-Fallet H, Airapetian
N, Lorne E, Levrard M, Seydi AA,
Amennouche N, Slama M, Dupont H
(2012) Improvement of left ventricular
relaxation as assessed by tissue Doppler
imaging in fluid-responsive critically ill
septic patients. Intensive Care Med
38:1461–1470
58. Saugel B, Fassio F, Hapfelmeier A,
Meidert AS, Schmid RM, Huber W
(2012) The T-line TL-200 system for
continuous non-invasive blood pressure
measurement in medical intensive care
unit patients. Intensive Care Med
38:1471–1477
59. Pierrakos C, Velissaris D, Scolletta S,
Heenen S, De Backer D, Vincent JL
(2012) Can changes in arterial pressure
be used to detect changes in cardiac
index during fluid challenge in patients
with septic shock? Intensive Care Med
38:422–428
60. Leatherman JW, Bastin-Dejong C,
Shapiro RS, Saavedra-Romero R (2012)
Use of expiratory change in bladder
pressure to assess expiratory muscle
activity in patients with large
respiratory excursions in central venous
pressure. Intensive Care Med
38:453–457
61. Hartog CS, Skupin H, Natanson C, Sun
J, Reinhart K (2012) Systematic
analysis of hydroxyethyl starch (HES)
reviews: proliferation of low-quality
reviews overwhelms the results of well-
performed meta-analyses. Intensive
Care Med 38:1258–1271
362
62. Thomas-Rueddel DO, Vlasakov V,
Reinhart K, Jaeschke R, Rueddel H,
Hutagalung R, Stacke A, Hartog CS
(2012) Safety of gelatin for volume
resuscitation—a systematic review and
meta-analysis. Intensive Care Med
38:1134–1142
63. Sandroni C, Cavallaro F, Marano C,
Falcone C, De Santis P, Antonelli M
(2012) Accuracy of plethysmographic
indices as predictors of fluid
responsiveness in mechanically
ventilated adults: a systematic review
and meta-analysis. Intensive Care Med
38:1429–1437
64. Tacon CL, McCaffrey J, Delaney A
(2012) Dobutamine for patients with
severe heart failure: a systematic review
and meta-analysis of randomised
controlled trials. Intensive Care Med
38:359–367
65. Polito A, Parisini E, Ricci Z, Picardo S,
Annane D (2012) Vasopressin for
treatment of vasodilatory shock: an
ESICM systematic review and meta-
analysis. Intensive Care Med 38:9–19
66. Schmittinger CA, Torgersen C, Luckner
G, Schroder DC, Lorenz I, Dunser MW
(2012) Adverse cardiac events during
catecholamine vasopressor therapy: a
prospective observational study.
Intensive Care Med 38:950–958
67. Balzer F, Wickboldt N, Spies C, Walder
B, Goncerut J, Citerio G, Rhodes A,
Kastrup M, Boemke W (2012)
Standardised drug labelling in intensive
care: results of an international survey
among ESICM members. Intensive
Care Med 38:1298–1305
68. Rhodes A, Ferdinande P, Flaatten H,
Guidet B, Metnitz PG, Moreno RP
(2012) The variability of critical care
bed numbers in Europe. Intensive Care
Med 38:1647–1653
69. Kanhere MH, Kanhere HA, Cameron
A, Maddern GJ (2012) Does patient
volume affect clinical outcomes in adult
intensive care units? Intensive Care
Med 38:741–751
70. Quenot JP, Rigaud JP, Prin S, Barbar S,
Pavon A, Hamet M, Jacquiot N,
Blettery B, Herve C, Charles PE,
Moutel G (2012) Suffering among
carers working in critical care can be
reduced by an intensive communication
strategy on end-of-life practices.
Intensive Care Med 38:55–61
71. Fuchs L, Chronaki CE, Park S, Novack
V, Baumfeld Y, Scott D, McLennan S,
Talmor D, Celi L (2012) ICU admission
characteristics and mortality rates
among elderly and very elderly patients.
Intensive Care Med 38:1654–1661
72. Song JU, Suh GY, Park HY, Lim SY,
Han SG, Kang YR, Kwon OJ, Woo S,
Jeon K (2012) Early intervention on the
outcomes in critically ill cancer patients
admitted to intensive care units.
Intensive Care Med 38:1505–1513
73. Gillies MA, McKenzie CA, Whiteley C,
Beale RJ, Tibby SM (2012) Safety of
nicotine replacement therapy in
critically ill smokers: a retrospective
cohort study. Intensive Care Med
38:1683–1688
74. Mosquera VX, Marini M, Muniz J,
Asorey-Veiga V, Adrio-Nazar B, Boix
R, Lopez-Perez JM, Pradas-Montilla G,
Cuenca JJ (2012) Traumatic aortic
injury score (TRAINS): an easy and
simple score for early detection of
traumatic aortic injuries in major
trauma patients with associated blunt
chest trauma. Intensive Care Med
38:1487–1496
75. McKinley S, Aitken LM, Alison JA,
King M, Leslie G, Burmeister E, Elliott
D (2012) Sleep and other factors
associated with mental health and
psychological distress after intensive
care for critical illness. Intensive Care
Med 38:627–633
76. Volpicelli G, Elbarbary M, Blaivas M,
Lichtenstein DA, Mathis G, Kirkpatrick
AW, Melniker L, Gargani L, Noble VE,
Via G, Dean A, Tsung JW, Soldati G,
Copetti R, Bouhemad B, Reissig A,
Agricola E, Rouby JJ, Arbelot C,
Liteplo A, Sargsyan A, Silva F,
Hoppmann R, Breitkreutz R, Seibel A,
Neri L, Storti E, Petrovic T (2012)
International evidence-based
recommendations for point-of-care lung
ultrasound. Intensive Care Med
38:577–591
77. Lamperti M, Bodenham AR, Pittiruti
M, Blaivas M, Augoustides JG,
Elbarbary M, Pirotte T, Karakitsos D,
Ledonne J, Doniger S, Scoppettuolo G,
Feller-Kopman D, Schummer W, Biffi
R, Desruennes E, Melniker LA,
Verghese ST (2012) International
evidence-based recommendations on
ultrasound-guided vascular access.
Intensive Care Med 38:1105–1117
78. Schnell D, Darmon M (2012) Renal
Doppler to assess renal perfusion in the
critically ill: a reappraisal. Intensive
Care Med 38:1751–1760
79. Lakhal K, Serveaux-Delous M, Lefrant
JY, Capdevila X, Jaber S (2012) Chest
radiographs in 104 French ICUs:
current prescription strategies and
clinical value (the RadioDay study).
Intensive Care Med 38:1787–1799
80. Rohacek M, Buatsi J, Szucs-Farkas Z,
Kleim B, Zimmermann H, Exadaktylos
A, Stoupis C (2012) Ordering CT
pulmonary angiography to exclude
pulmonary embolism: defense versus
evidence in the emergency room.
Intensive Care Med 38:1345–1351
81. Barrett KA, Ferguson ND, Athaide V,
Cook DJ, Friedrich JO, McDonald E,
Pinto R, Smith OM, Stevenson J, Scales
DC (2012) Surrogate decision makers’
attitudes towards research decision
making for critically ill patients.
Intensive Care Med 38:1616–1623
82. Mehta S, Quittnat Pelletier F, Brown M,
Ethier C, Wells D, Burry L, MacDonald
R (2012) Why substitute decision
makers provide or decline consent for
ICU research studies: a questionnaire
study. Intensive Care Med 38:47–54
83. Schenker Y, Tiver GA, Hong SY,
White DB (2012) Association between
physicians’ beliefs and the option of
comfort care for critically ill patients.
Intensive Care Med 38:1607–1615
84. Forte DN, Vincent JL, Velasco IT, Park
M (2012) Association between
education in EOL care and variability in
EOL practice: a survey of ICU
physicians. Intensive Care Med
38:404–412
85. Barnato AE, Tate JA, Rodriguez KL,
Zickmund SL, Arnold RM (2012)
Norms of decision making in the ICU: a
case study of two academic medical
centers at the extremes of end-of-life
treatment intensity. Intensive Care Med
38:1886–1896
86. Azoulay E, Garrouste M, Goldgran-
Toledano D, Adrie C, Max A, Vesin A,
Francais A, Zahar JR, Cohen Y,
Allaouchiche B, Schlemmer B, Timsit
JF (2012) Increased nonbeneficial care
in patients spending their birthday in
the ICU. Intensive Care Med
38:1169–1176
87. Bulow HH, Sprung CL, Baras M,
Carmel S, Svantesson M, Benbenishty
J, Maia PA, Beishuizen A, Cohen S,
Nalos D (2012) Are religion and
religiosity important to end-of-life
decisions and patient autonomy in the
ICU? The Ethicatt study. Intensive Care
Med 38:1126–1133
88. Quenot JP, Rigaud JP, Prin S, Barbar S,
Pavon A, Hamet M, Jacquiot N,
Blettery B, Herve C, Charles PE,
Moutel G (2012) Impact of an intensive
communication strategy on end-of-life
practices in the intensive care unit.
Intensive Care Med 38:145–152
363
89. Ouanes I, Stambouli N, Dachraoui F,
Ouanes-Besbes L, Toumi S, Ben Salem
F, Gahbiche M, Abroug F (2012)
Pattern of end-of-life decisions in two
Tunisian intensive care units: the role of
culture and intensivists’ training.
Intensive Care Med 38:710–717
90. Louriz M, Abidi K, Akkaoui M, Madani
N, Chater K, Belayachi J, Dendane T,
Zeggwagh AA, Abouqal R (2012)
Determinants and outcomes associated
with decisions to deny or to delay
intensive care unit admission in
Morocco. Intensive Care Med
38:830–837
91. Gristina GR, Martin E, Ranieri VM
(2012) Regulation of advance directives
in Italy: a bad law in the making.
Intensive Care Med 38:1897–1900
92. Bein T, Hackner K, Zou T, Schultes S,
Bosch T, Schlitt HJ, Graf BM, Olden
M, Leitzmann M (2012) Socioeconomic
status, severity of disease and level of
family members’ care in adult surgical
intensive care patients: the prospective
ECSSTASI study. Intensive Care Med
38:612–619
93. Mealer M, Jones J, Moss M (2012) A
qualitative study of resilience and
posttraumatic stress disorder in United
States ICU nurses. Intensive Care Med
38:1445–1451
364
